Department of Inflammation Biology, Centre for Rheumatic Diseases, School of Immunology & Microbial Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Department of Rheumatology, King's College Hospital, London, UK.
Rheumatology (Oxford). 2021 May 14;60(5):2040-2045. doi: 10.1093/rheumatology/keaa840.
People with rheumatic and musculoskeletal diseases (RMDs) are facing several challenges during the COVID-19 pandemic, such as poor access to regular health services and drug shortages, particularly in developing countries. COVID-19 represents a syndemic, synergistic condition that interacts with and exacerbates pre-existing diseases such as RMDs, other co-morbidities and social conditions. The emerging evidence on both biological and non-biological factors implicated in worse outcomes in people with RMDs affected by the COVID-19 pandemic, whether infected by the virus or not, calls for the need to use more novel and holistic frameworks for studying disease. In this context, the use of a syndemic framework becomes particularly relevant. We appeal for a focus on the identification of barriers and facilitators to optimal care of RMDs in the context of the COVID-19 pandemic, in order to tackle both the pandemic itself and the health inequities inherent to it.
患有风湿和肌肉骨骼疾病（RMDs）的人在 COVID-19 大流行期间面临着多种挑战，例如难以获得常规医疗服务和药品短缺，尤其是在发展中国家。COVID-19 代表了一种综合征，一种协同的病症，它与 RMD 等先前存在的疾病、其他合并症和社会状况相互作用并使其恶化。关于 COVID-19 大流行期间受影响的 RMD 患者（无论是否感染病毒）的生物和非生物因素对更差结果的影响的新出现证据表明，需要使用更新颖和全面的框架来研究疾病。在这种情况下，使用综合征框架变得尤为重要。我们呼吁关注在 COVID-19 大流行背景下确定 RMD 最佳护理的障碍和促进因素，以解决大流行本身及其固有的健康不平等问题。
